Genetic variation within hepatitis B surface antigen (HBsAg), in particular within the major hydrophobic region (MHR), is related to immune/vaccine and test failures and can have a significant impact on the vaccination and diagnosis of acute infection. This study shows, for the first time, variation among acute cases and compares the amino acid variation within the HBsAg between acute and chronic infections. We analyzed the virus isolated from 1231 acute and 585 chronic cases reported to an anonymized public health surveillance database between 2004 and 2014 in The Netherlands.
prevalence of chronic HBV infection in The Netherlands is 0.2% to 0.5%. 5, 6 HBV is classified in 10 HBV genotypes, designated A to J, based on phylogenetic analysis of the S gene and full-length genome. 7 The and the e antigen [HBeAg] ), the DNA polymerase, and gene x, which acts as a transactivator for replication.
The HBV genome is one of the most variable among DNA viruses.
In particular, variation in the major hydrophobic region (MHR; amino acids 100 to 160) of the HBsAg has been related to reduced or absent immune/vaccine responses (immune/vaccine escape), may impact the detection of HBsAg, or lead to reactivation in persons with previously resolved infection or immunosuppressed persons (often receiving immunosuppressive treatment) with stable chronic infection. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] This study shows, for the first time, variation among acute HBV infections as well as a comparison of the HBsAg amino acid variation between acute and chronic infections.
2 | METHODS
| Study population
In The Netherlands, all acute HBV infections are anonymously notified to OSIRIS by the municipal health services. OSIRIS is a public health database used for surveillance. Clinical, patient, and test data on HBV markers are not reported, which did not allow further analysis of the relation of levels of different HBV markers and substitutions. 
| HBV genotype and variant identification
S-region sequences were used to determine the genotype of the HBV by comparing them to reference strains using Bionumerics version 7.1 (SintMartens-Latem, Belgium). 36 Phylogenetic trees were constructed using the maximum parsimony method. To assess genetic variation within the HBsAg and RT, we analyzed the appearance and frequency of amino acid sequence variation within the S and RT genes by type by aligning all sequences using Bionumerics version 7.1 to the sequences of the reference HBV types (A to J) assigned by Pourkarim et al. 7 Subgenotypespecific polymorphisms were excluded in the analysis. All sequences were deposited in GenBank (accession numbers: KX659172 to KX659981 and KP243601 to KP244031). For clarity, strains isolated from acute infected cases are referred to as acute strains and strains isolated from chronic cases, as chronic strains.
| Statistical analysis
Statistical analyses were performed using the univariate Χ 2 test.
A 2-sided P < .01 was considered statistically significant. GtD was the second most dominant type and was detected in 17.4% (n = 214) of the acute cases and 34.2% (n = 200) of the chronic cases (Table 1) . A majority of the acute gtD cases were born in The Netherlands (66.8%), followed by Turkey (8.4%), whereas this was reversed among chronic cases, where a majority of chronic GtD cases were born in Turkey (33.5%), followed by The Netherlands (12.5%).
For acute GtB, C, D, and E, The Netherlands was the predominant country of birth. In contrast, for chronic GtB and GtC, most cases were born in China (25.4% and 50.0%, respectively), and for GtE, almost all cases (98%) were born in African countries.
A majority of the acute cases were not vaccinated (91%, n = 1117). For 5% (n = 66) vaccination was complete/incomplete, and for 4% (n = 48) vaccination status was unavailable. In contrast to the vaccination status of acute strains, the vaccination status in a majority of the chronic cases notified in OSIRIS (>2010) was unavailable (74%, n = 434). Twenty-five percent (n = 144) were not vaccinated, and in 1% (n = 7), vaccination was either complete or incomplete. No vaccination data of chronic cases before 2010 could be obtained.
Overall, acute and chronic HBV infections were more frequently reported in men, 79% and 63%, respectively ( Figure 1 ), and the median age of infection among acute cases was 41 years. The median age of infection among chronic cases cannot be assessed as cases are reported as chronically infected and not when (acute) infection has occurred.
| HBsAg variation among acute cases
The HBsAg amino acid sequences of the 6 genotypes were analyzed and compared to their respective reference type. 7 Of the 1231 acute strains, 19.7% (n = 242) harbored variation in the HBsAg ranging from a single substitution (14.3%, n = 176) to a combination of 2 to 9 substitutions (5.4%, n = 66). The HBsAg variation among acute GtA strains was the lowest and was significantly lower than that found for GtB, D, and E strains (Table 1 and Figure 2) . In total, 100 GtA strains (11.9% of 839 GtA strains; Table 1 ) harbored HBsAg variation, ranging from a single substitution (9.9%, n = 83) to a combination of 2 to 6 substitutions (2%, n = 17) per strain ( Figure 2 ). In comparison, GtB, C, D, E, and F strains harbored HBsAg variation in 41.9%, 21.3%, 41.1%, 39.2%, and 22.9%, respectively ( Table 1) . Combinations of substitutions were the most frequently found for GtD acute strains, ranging from 2 to 9 substitutions (14.5%, n = 31 ; Figure 2 ).
Combinations of substitutions were the lowest for GtB, C, E, and F strains and ranged from 2 substitutions per strain (GtF) to 2 to 3 substitutions per strain (GtB and C) and 2 to 5 substitutions per strain (GtE; Figure 2 ).
In total, we found 105 acute strains (8.5%) with 120 different substitutions divided over 29 positions within the MHR (Table 1 and were significantly lower (P < .01) compared to GtD (Table 1) . One GtF strain showed only one MHR substitution, which was described as an immune escape substitution having an impact on HBsAg detection:
G145R. The patient was fully vaccinated at the time of diagnosis, yet was found to be HBsAg positive. Other substitutions described as immune escape and/or to have been associated with HBsAg test failure were found among GtA, B, D, and E, totaling up to 50 strains harboring these substitutions as a single substitution or in combination (4.1% of all acute strains; Table 2 ). Apart from the GtF case, 3
other cases (GtD) were found to be vaccinated (1 complete/2 incomplete), yet were HBsAg positive, and were infected with a variant harboring a single MHR substitution (M103I or T118A or P127I), of which only M103I was associated with HBsAg test failure (Table 2) . Data on whether the cases were nonresponders could not be assessed as data were anonymized.
Almost all cases were HBsAg positive as this was a reporting criterion to OSIRIS. However, 3 cases (GtD) were HBsAg-negative HBcAg test result led to their notification.
| HBsAg variation among chronic infected cases
The HBsAg amino acid sequences of the chronic strains were compared to the respective reference type. 7 Of the 585 chronic strains, more than half of the strains (52.8%, n = 309) harbored variation within the HBsAg, ranging from a single substitution (24.4%, n = 143) or a combination of 2 to 10 substitutions per strain (28.4%, n = 166). The variation was high for GtA (42.2%), GtB (70.6%), GtC (56.3%), GtD (55.0%), and GtE (62.7%; Table 1 ). The genetic HBsAg variation was the lowest for GtF, with only 1 (16.7%) strain (1 substitution outside the MHR; Figure 2 ).
The combination of substitutions per strain was the highest for GtC and ranged from a combination of 2 to 10 substitutions (25%, n = 12) per strain ( Figure 2 ). This was followed by GtB, GtD, and GtA, with a combination of 2 to 8 substitutions for GtA (22.1%, n = 45) and GtB (45.6%, n = 31) and 2 to 9 for gtD (33.0%, n = 66; was significantly (P < .01) higher than that found among GtA (24 strains with 30 substitutions) and other genotypes (Table 1) .
Substitutions described as an immune escape substitution and/or
to have an impact on HBsAg detection ( 
| RT substitutions
Owing to the overlapping nature of the S gene over the polymerase, sequence analysis of the RT region of the polymerase was additionally conducted to identify antiviral resistance markers.
The acute HBsAg substitutions resulted in 444 different substitutions in the RT region of the polymerase among 335 strains (Table 3) . Among the chronic strains, 604 different substitutions were found among 321 chronic cases. Five different substitutions were described to confer antiviral resistance against Lamuvidine, Entecavir, and Telibividune. Substitutions that were found to confer reduced susceptibilty against Adefovir and Tenofovir 39,40 were found in 3 acute strains (GtA (n = 2), and GtD (n = 1) and 5 GtA chronic strains (Table 3) . Substitutions L180M and M204V were always found in combination, appearing as double substitutions in 1 acute and 5 chronic GtA strains, and with V173L as a triple substitution in 1 acute GtA strain.
| HBsAg stop codons
We identified 7 acute strains (0.6%) and 7 chronic strains (1.2%) that
were infected with a variant with a stop codon within the HBsAg gene that could result in truncated expression of the HBsAg: L15STOP (n = 1 acute and n = 2 chronic), residue S61STOP (n = 2 acute), C69STOP (n = 1 acute and n = 1 chronic), W165STOP (n = 1 acute and n = 1 chronic), L175STOP (n = 1 acute), W182STOP (n = 1 acute and n = 1 chronic), and W199 STOP (n = 2 chronic).
Stop codon W182 resulted in the drug-resistant substitution (V173L) described above. All cases were reported based on a positive
HBsAg test result.
| DISCUSSION
This study shows, for the first time, variation among acute cases as well as a comparison of the genetic variation of the HBsAg and the MHR region between acute and chronic HBV cases diagnosed in The Netherlands. We should point out that the data set for acute cases is a representative set of acute HBV in The Netherlands, whereas the data set for chronic cases represents only those with risk behavior from various risk groups (<2010) and in most cases from MSM (>2010).
We showed that 6 genotypes continue to circulate in The Netherlands, 27, 31 of which GtA is the dominant genotype, followed by GtD among both acute and chronic cases. However, GtD showed significantly more variation over the entire HBsAg and within the MHR than GtA or any other genotype among both acute and chronic cases.
Overall, the variation among the chronic strains for all of the genotypes was significantly higher than that for acute strains. Twenty percent of the acute strains harbored variation within the HBsAg, whereas more than half of the chronic strains (53%) harbored variation within the HBsAg. Other studies have shown similar percentages, ranging from 40% to 55% variation, which were mostly among chronic GtD strains. 11, [41] [42] [43] The low diversity among GtA acute strains suggests that the transmission of GtA 8,9 is sustained within the MSM community in The Netherlands 44, 45 and that there is little transmission from chronic cases leading to new infections. In contrast, the high variation among acute GtB, D, and E most likely represents transmission from chronically infected cases, as shown by Kretzschmar et al. 44 
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T 23, 46 or to reactivation in individuals with previously resolved infection or immunosuppressed individuals with stable chronic infection. 24 As such, the circulation of variants, in particular, those affecting immune or vaccination response, is a major public health concern. As the clinical background of the cases, whether the acute infection was resolved or chronic cases were immunosuppressed (by therapy), was unknown, variation as for reactivation could not be taken into account.
In our study, we found 18.6% of chronic strains to harbor a substitution with the MHR, which varied from 0% for GtF to 28% for GtB; this is in line with data from other studies describing a prevalence of these substitutions ranging from 14% to 44% worldwide. 11, [47] [48] [49] [50] [51] This was significantly higher compared to acute strains (8.6%), where we show, for the first time, prevalence data on acute strains. and infection modeling indicated that the frequency of VEMs will increase in 50 years' time. 54 The immune escape substitution has also been described to be associated with HBsAg test failure. 41 who found no relation between a stop codon and a false-negative test result.
Our study comprises, for the most part, HBsAg-positive cases, as this is one of the reporting criteria, and we therefore may have or are missing cases that indeed cannot be detected by current assays. It should be noted that current HBV surface antigen assays are able to detect most MHR variants that previously failed detection, and indeed the substitutions found in our study were among the acute strains As the region of the S gene analyzed overlaps with the RT gene of the polymerase, variation of the RT gene could be analyzed for antiviral resistance with 0.4% of the acute strains and 1.0% of the chronic strains having a substitution associated with antiviral resistance. 39, 40 However, data on treatment are not included in the database, and further conclusions could not be drawn from these data.
The anonymized data also limited the analysis of different HBV markers, which are not reported on HBsAg variation frequency; it has been shown that the levels of different HBV markers can influence the variation frequency. 57, 58 In addition, various laboratories use different assays, and the data on HBsAg level/DNA level that may vary between assays 57 cannot be assessed using retrospective data and a new prospective study with standardized platforms needs to be conducted.
In conclusion, this study is the first to report on HBsAg variation among acute cases and to make a comparison of HBV acute and chronically infected cases in The Netherlands. The study shows significant differences of variation between both acute and chronic cases. These findings indicate the necessity of monitoring and studying amino acid substitutions, which can have an impact on vaccine effectiveness and HBsAg testing. Furthermore, the diagnostic testing algorithms/assays should be evaluated further to exclude underreporting of false HBsAg-negative cases.
